NCT07705074Not yet recruitingPhase 1/2
FAPI PET Imaging - An Exploratory Study
FAPI PET Imaging - a Multicentric Exploratory Evaluation
Source: ClinicalTrials.gov · Last updated 15 Jul 2026
Brief summary (registry, in English)
This study is testing a new imaging tracer called \[18F\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis. \[18F\]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well. People who join this study will get one injection of the tracer into a vein, then have one PET/CT or PET/MR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed. The study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 770 (estimated)
- First submitted
- 1 Jul 2026
- Start date
- Aug 2026
- Primary completion date
- Sept 2029
- Lead sponsor
- Martin Huellner
- Diseases
- Prostate cancer, Bladder cancer, Head and neck cancer, Thyroid cancer, Mesothelioma, Lung cancer, Pancreatic cancer, Liver and biliary tract cancer, Gastric and esophageal cancer, Multiple myeloma, Endometriosis
- NCT number
- NCT07705074
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 770
- From Aug 2026 to the primary completion date, Sept 2029
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy.
- Previous hypersensitivity reactions to radiotracer administration
- Participants scheduled for PET/MR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.
Other
- Severe claustrophobia that would preclude PET imaging.
- Inability to remain still for the duration of the PET/MR examination.
- Inability to understand the study information, for example due to language barriers.
- Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).
Who the study is looking for
- Written informed consent obtained and documented by the participant's signature.
- Age ≥18 years at the time of consent.
- Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol.
- Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT/MRI) to allow comparative evaluation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kantonsspital Baden Coordinator of this site? Confirm its status | Baden | Switzerland | Unknown status |
| Hôpitaux Universitaires de Genève (HUG) Coordinator of this site? Confirm its status | Geneva | Switzerland | Unknown status |
| Clinique de Genolier Coordinator of this site? Confirm its status | Genolier | Switzerland | Unknown status |
| Luzerner Kantonsspital Coordinator of this site? Confirm its status | Lucerne | Switzerland | Unknown status |
| Department for Nuclear Medicine, University Hospital Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.